LONDON--(Marketwire - May 03, 2010) - ChromoCure, Inc. (PINKSHEETS: KKUR) and Genome Research Group (GRG) continue their joint expansion and increased capabilities in response to the surge of aneuploidy/chromosomal theory of cancer research and worldwide collaboration.
In fact, the European Molecular Biology Organization (EMBO) will be holding their Aneuploidy2010 workshop June 19th - 23rd at and in conjunction with the University of Edinburgh's Centre for Cell Biology, one of nine UK-based Wellcome Trust Centres, three of which are in Scotland.
The Wellcome Trust is a global charity dedicated to achieving extraordinary improvements in human and animal health and the support of the brightest minds in biomedical research and the medical humanities.
Today EMBO has more than 1400 members in Europe and close to 90 associate members worldwide -- providing a dedicated focal point for the vast network of molecular biology. The organization runs an extended programme of activities ranging from fellowships, courses and workshops to science & society activities and scientific publications. EMBC has since grown to 27 member states including many European Union countries and beyond.
The aim Aneuploidy2010 is to bring group leaders, Ph.D. students and postdoctoral fellows working on chromosome segregation together with their peers working on mechanisms and consequences of aneuploidy. In excess of 36 world experts are already confirmed a speakers.
Thus the overall goal is to help cell biologists better understand key concepts and the latest results in aneuploidy in order to help guide their future research directions, whilst also informing those working on the applied study of aneuploidy to ensure that they are exposed to the cutting edge of international mitosis research.
The Mayo Clinic's recent landmark findings confirming aneuploidy as the cause of cancer were published in the December 2009 Cancer Cell journal. This publication has spurred increased worldwide research by a number of respected research universities and institutions, all of which have published similar reports in 2010.
The Company recently announced the Euro Zone launch of its Pathologist Collaborative Research (PCR) Program in support of the groundbreaking Project Boveri: Find the Cure Initiative; as the companies leverage their combined technologies, research knowledge and industry relationships.
The Company will announce programs and specifics for each Euro-Zone country as its lead partner in the area is selected.
The Company's recently announced merger with GRG prepares the group for a leading role in the new era of cancer research, detection, and therapy.
Research has conclusively and irrefutably demonstrated aneuploidy a more accurate predictor of cancer than cytological/histological analysis or genetic marker-based diagnostics that are the only other methods in existence today. ChromoCure's proprietary technology and understanding of cancer compliment GRG's non-toxic and non-invasive approaches to cancer therapy and cure research.
The Company's focus on cancer research is further underscored by recent major clinical publications that both validate ChromoCure's chromosomal/aneuploidy theory of cancer and establish the company's detection approach as the forefront of both cancer detection and research.
GRG's advanced Therapeutic Modeling Protocols, together with ChromoCure's landmark Chromosomal Scanning Technology, further strengthens the Company's leadership in Cancer Detection, Therapy and Cure by providing on-demand, real-time cancer progression analysis to monitor and determine treatment efficacy.
The Company's recently announced merger with GRG will be of mutual benefit in advancement of their shared objective; as a focused Cancer Therapy and Cure Research & Development organization. The announced merger and acquisition of GRG prepares the group for a leading role in this new era of cancer research, detection and therapy.
The combined entity will possess complementary detection and therapeutic technology and protocols. Management believes the transaction to be of significant long-term shareholder value and furthers the Company's transition to research, technology development, and licensing as a source of significant long-term and recurring revenues and equity appreciation.
The Company believes its technologies provide the foundation for significant advances in diagnosis, therapy and cure. The Company recently announced its Therapy and Cure initiatives with Project Boveri: Find the Cure. Shareholders can expect further updates on research collaborations, laboratory partnerships, and research initiatives.
The Company's goal is to establish a worldwide network of diagnostic and research collaborations with continuous collection of cancer specimen and test result data.
About ChromoCure ChromoCure develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company's proprietary CS200 Chromosomal Scanner has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure. The Company also applies its technology and knowledge to cancer cure and therapeutics research.
About Genome Research Group The Genome Research Group develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company's proprietary cancer detection system locates and measures unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has a proven and effective accuracy of 100% for all cancers at all stages. The Company's proprietary Therapeutic Modeling Protocols provide statistical modeling and prediction tools for the measurement and monitoring of cancer progression and remission. The Company also applies its technology and knowledge to cancer cure and therapeutics research. GRG owns proprietary techniques for non-toxic and non-invasive cancer therapy utilizing hypothermic modulation and resonance. GRG's advanced Therapeutic Modeling and Treatment Protocols combined with its industry and medical research collaborations validate its leadership role in Cancer Detection, Therapy and Cure.
Safe-Harbor Statement This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.